Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200 Day Moving Average – Here’s Why

Champions Oncology, Inc. (NASDAQ:CSBR)’s stock price crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $5.72 and traded as low as $4.80. Champions Oncology shares last traded at $5.00, with a volume of 35,201 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Champions Oncology from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, September 16th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Champions Oncology Stock Up 1.2%

The company has a fifty day simple moving average of $5.14 and a 200-day simple moving average of $5.71. The firm has a market cap of $68.76 million, a P/E ratio of -61.75 and a beta of 0.44.

Champions Oncology (NASDAQ:CSBR) last posted its quarterly earnings results on Thursday, September 10th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. Champions Oncology had a negative return on equity of 25.77% and a negative net margin of 1.82%.The business had revenue of $15.23 million for the quarter, compared to analysts’ expectations of $15.04 million.

Hedge Funds Weigh In On Champions Oncology

A hedge fund recently bought a new position in Champions Oncology stock. Bank of New York Mellon Corp bought a new position in Champions Oncology, Inc. (NASDAQ:CSBR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 21,614 shares of the biotechnology company’s stock, valued at approximately $133,000. Bank of New York Mellon Corp owned about 0.16% of Champions Oncology at the end of the most recent quarter. 41.30% of the stock is currently owned by institutional investors.

Champions Oncology Company Profile

Champions Oncology, Inc is a biotechnology company that provides translational oncology services and data-driven solutions for cancer research and drug development. The company works with pharmaceutical and biotechnology organizations to help evaluate potential cancer therapies, identify responsive patient populations and support precision-medicine programs.

Its offerings include patient-derived xenograft and other tumor models, in vitro and in vivo testing, genomic and molecular profiling, biomarker analysis, and oncology data analytics.